EGFR and non-small cell lung carcinoma: To explore this clinical question, we conducted a retrospective study of the effectiveness, safety, and proportion of EGFR-TKI rechallenge treatment after first-line EGFR-TKI received in elderly patients (over 75 years of age) with advanced NSCLC harboring EGFR mutations.